BerGenBio ASA (OSL:BGBIO)

Norway flag Norway · Delayed Price · Currency is NOK
1.168
+0.008 (0.69%)
At close: Oct 23, 2025
0.69%
Market Cap45.65M
Revenue (ttm)5.41M
Net Income (ttm)-107.58M
Shares Out39.09M
EPS (ttm)-2.75
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,633
Average Volume104,467
Open1.130
Previous Close1.160
Day's Range1.130 - 1.198
52-Week Range1.020 - 15.670
Beta1.19
RSI48.83
Earnings DateNov 19, 2025

About BerGenBio ASA

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory disease in Norway. It develops BGBIL025, a JAK2 inhibitor indicated, which is in Ph1b/2a for treatment of the bone marrow disorder myelofibrosis. The company was incorporated in 2007 and is based in Bergen, Norway. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 13
Stock Exchange Oslo Børs
Ticker Symbol BGBIO
Full Company Profile

Financial Performance

In 2024, BerGenBio ASA's revenue was 848,000, an increase of 139.55% compared to the previous year's 354,000. Losses were -139.28 million, -26.85% less than in 2023.

Financial Statements

News

BerGenBio ASA (STU:7BG0) Q4 2024 Earnings Call Highlights: Strategic Review and Financial ...

BerGenBio ASA (STU:7BG0) Q4 2024 Earnings Call Highlights: Strategic Review and Financial Management in Focus

8 months ago - GuruFocus